Medical Treatment Technologies Research Articles

Psychological distress, sexual satisfaction and quality of life of gynaecological cancer patients and their spouses during cancer survivorship: A comparison of husbands and wives.

To investigate the psychological distress, sexual satisfaction, and quality of life of gynaecological cancer survivors and their spouses during cancer survivorship. The survival rate of patients with cancer is increasing owing to advances in medical treatment technology. Spouses are the closest companions of gynaecological cancer survivors. Patients with gynaecological cancer and their spouses face different situations and challenges after experiencing cancer invasion. Questionnaire-based cross-sectional study. Convenience sampling was employed, and 180 participants, including patients with gynaecological cancer and their spouses, were enrolled. A structured questionnaire was used to investigate the psychological distress, sexual satisfaction, and quality of life of gynaecological cancer survivors and their spouses during acute, extended, and permanent survivorship. The STROBE checklist guided the study preparation. For gynaecological cancer survivors and their spouses, (1) severe psychological distress was present during acute survivorship, with anxiety extending until permanent survivorship; (2) no significant differences were observed in pre- and post-treatment sexual satisfaction, although pre-treatment sexual satisfaction was higher than post-treatment sexual satisfaction in all three cancer survivorship stages and (3) quality of life decreased during acute survivorship and gradually improved with time. Psychological distress, sexual satisfaction and quality of life of gynaecological cancer survivors and their spouses worsened during acute survivorship and improved over time until permanent survivorship. Gynaecological cancer survivors and their spouses experience anxiety and depression from diagnosis confirmation until permanent survivorship (>5 years survival). Therefore, clinical nurses' sensitivity to emotional distress in cancer survivors and their spouses can be improved and a consistent and routine evaluation method has been established for the early detection of such emotional distress. The results of this study can provide a reference for clinical healthcare professionals and contribute to a better quality of care.

Biomedical Application of Magnetic Nanoparticles: A Review

Medical treatment technologies in healthcare industries are modernized by using nanoparticles. The effect of nanoparticles and their interaction on human cells show many significant results. In this paper, I have studied the experimental and theoretical background of some biomedical applications of nanoparticles. It is found that gold (Au), silver (Ag), iron (Fe), silica (SiO2), and some polymeric nanoparticles are extensively used in the treatment of various deadly diseases. The nanoparticles of gold, silver, zinc oxide, silica, and cerium oxide are studied mostly to investigate the suitable distribution methodology for medical diagnosis and treatment.

Local infrared radiation combined with skin regenerative medical technology for treatment of incision infection after open gastrointestinal surgery: Efficacy and influence on IL-4/IL-13/STAT6 signaling pathway

Local infrared radiation combined with skin regenerative medical technology for treatment of incision infection after open gastrointestinal surgery: Efficacy and influence on IL-4/IL-13/STAT6 signaling pathway

External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases.

PATHFx is a clinical decision-support tool based on machine learning capable of estimating the likelihood of survival after surgery for patients with skeletal metastases. The applicability of any machine-learning tool depends not only on successful external validation in unique patient populations but also on remaining relevant as more effective systemic treatments are introduced. With advancements in the treatment of metastatic disease, it is our responsibility to patients to ensure clinical support tools remain contemporary and accurate. Therefore, we sought to (1) generate updated PATHFx models using recent data from patients treated at one large, urban tertiary referral center and (2) externally validate the models using two contemporary patient populations treated either surgically or nonsurgically with external-beam radiotherapy alone for symptomatic skeletal metastases for symptomatic lesions. After obtaining institutional review board approval, we collected data on 208 patients undergoing surgical treatment for pathologic fractures at Memorial Sloan Kettering Cancer Center between 2015 and 2018. These data were combined with the original PATHFx training set (n = 189) to create the final training set (n = 397). We then created six Bayesian belief networks designed to estimate the likelihood of 1-month, 3-month, 6-month, 12-month, 18-month, and 24-month survival after treatment. Bayesian belief analysis is a statistical method that allows data-driven learning to arise from conditional probabilities by exploring relationships between variables to estimate the likelihood of an outcome using observed data. For external validation, we extracted the records of patients treated between 2016 and 2018 from the International Bone Metastasis Registry and records of patients treated nonoperatively with external-beam radiation therapy for symptomatic skeletal metastases from 2012 to 2016 using the Military Health System Data Repository (radiotherapy-only group). From each record, we collected the date of treatment, laboratory values at the time of treatment initiation, demographic data, details of diagnosis, and the date of death. All records reported sufficient follow-up to establish survival (yes/no) at 24-months after treatment. For external validation, we applied the data from each record to the new PATHFx models. We assessed calibration (calibration plots), accuracy (Brier score), discriminatory ability (area under the receiver operating characteristic curve [AUC]). The updated PATHFx version 3.0 models successfully classified survival at each time interval in both external validation sets and demonstrated appropriate discriminatory ability and model calibration. The Bayesian models were reasonably calibrated to the Memorial Sloan Kettering Cancer Center training set. External validation with 197 records from the International Bone Metastasis Registry and 192 records from the Military Health System Data Repository for analysis found Brier scores that were all less than 0.20, with upper bounds of the 95% confidence intervals all less than 0.25, both for the radiotherapy-only and International Bone Metastasis Registry groups. Additionally, AUC estimates were all greater than 0.70, with lower bounds of the 95% CI all greater than 0.68, except for the 1-month radiotherapy-only group. To complete external validation, decision curve analysis demonstrated clinical utility. This means it was better to use the PATHFx models when compared to the default assumption that all or no patients would survive at all time periods except for the 1-month models. We believe the favorable Brier scores (< 0.20) as well as DCA indicate these models are suitable for clinical use. We successfully updated PATHFx using contemporary data from patients undergoing either surgical or nonsurgical treatment for symptomatic skeletal metastases. These models have been incorporated for clinical use on PATHFx version 3.0 (https://www.pathfx.org). Clinically, external validation suggests it is better to use PATHFx version 3.0 for all time periods except when deciding whether to give radiotherapy to patients with the life expectancy of less than 1 month. This is partly because most patients survived 1-month after treatment. With the advancement of medical technology in treatment and diagnosis for patients with metastatic bone disease, part of our fiduciary responsibility is to the main current clinical support tools. Level III, therapeutic study.

Establishment and practice of training mode for students majoring in minimally-invasive and noninvasive medical talents

Medical treatment technology has made a lot of breakthrough because of the rapid development of the medical devices industrial.Minimally-invasive and noninvasive medicine is the development tendency of the future medicine.To adapt to the needs of the future medicine,Chongqing medical university exerted much efforts on training of minimally-invasive and noninvasive medical talents.We explored and practiced in aspects of fixing educational conception and goal,building curriculum and teaching content,constructing professional teaching team and developing practice and innovation abilities in order to fill the void of personnel training in the minimally-invasive and noninvasive medical field. Key words: Minimally-invasive and noninvasive medicine; Talents traininga; Mode

Evaluation of the efficacy of introduction of a new medical technology fortreatment of chronic dermatoses based on the application of activated zincpyrithione

The article presents the results of evaluating the efficacy of introduction of a medical technology known as application of Skin-Cap (activated zinc pyrithione) in the therapy of chronic dermatoses in the course of a questionnaire survey of 303 dermatovenerologists from 14 Russian cities. The authors revealed that the doctors awareness of this medical technology resulted in a considerable growth of the percentage of patients who receive activated zinc pyrithione. The respondents mentioned the efficacy, safety and simple use of the drug and algorithms of its administration disclosed in the medical technology. It was revealed that compliance with the medical technology results in the lower frequency of visits to a doctor for evaluating the efficacy of treatment and lower need in its correction. The respondents also noted an improvement in the patients attitude to their treatment.